Stock Performance and Market Context
On 06 Aug 2026, Sudeep Pharma Ltd’s stock price surged to Rs.988.7, setting a new 52-week and all-time high. The stock opened with a gap up of 2.5% and recorded an intraday high gain of 3.38%, outperforming its sector by 1.08%. The day’s closing gain stood at 1.45%, significantly ahead of the Sensex’s 0.31% rise on the same day.
The stock has demonstrated strong momentum, registering gains for three consecutive days and delivering an 11.73% return during this period. Over longer horizons, Sudeep Pharma’s performance has been notably superior to the benchmark Sensex. Year-to-date, the stock has appreciated by 61.05%, while the Sensex declined by 7.50%. Over one month, the stock gained 18.28% compared to the Sensex’s 0.69%, and over three months, it surged 43.86% against the Sensex’s 1.11% rise.
Technical Indicators and Trend Analysis
The technical outlook for Sudeep Pharma Ltd remains mildly bullish. The stock is trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained buying interest. The current trend shifted from sideways to mildly bullish on 03 Jul 2026 at a price level of Rs.866.45.
Technical indicators provide a mixed but generally positive picture. The MACD and Bollinger Bands are bullish on a weekly basis, while the Dow Theory indicates a bullish trend monthly. The Relative Strength Index (RSI) currently shows no clear signal, suggesting the stock is not yet overbought. Immediate support is established at the 52-week low of Rs.524.95, while the major resistance levels previously noted at Rs.730.44 (100 DMA) have been decisively surpassed, with the new resistance now at the all-time high of Rs.988.7.
Valuation Metrics and Financial Quality
At the current price of Rs.970.25 (as of 06 Aug 2026, 09:50 AM), Sudeep Pharma Ltd trades at a price-to-earnings (P/E) ratio of 59x on a trailing twelve months (TTM) basis. The price-to-book value stands at 12.23x, while enterprise value multiples include EV/EBITDA at 48.84x and EV/EBIT at 52.33x. The EV/Sales multiple is 16.87x, and EV/Capital Employed is 11.79x. Dividend yield remains modest at 0.16%, with the latest dividend declared at Rs.1.50 per share and an ex-dividend date of 23 Jul 2026.
Quality assessments highlight a strong balance sheet and financial discipline. The company exhibits excellent capital structure with low leverage, reflected in an average debt to EBITDA ratio of 0.72 and net debt to equity at zero. Interest coverage is robust at 33.98x, indicating comfortable ability to service debt. Return on capital employed (ROCE) is strong at 24.88%, underscoring efficient utilisation of capital. Management risk is rated good, and there is no promoter share pledging, which supports confidence in governance.
Delivery Volumes and Market Participation
Recent delivery volumes indicate heightened market activity. On 05 Aug 2026, delivery volume reached 5.24 lakh shares, accounting for 29.89% of total volume, significantly above the five-day average of 1.36 lakh shares. The trailing one-month average delivery volume stands at 1.23 lakh shares, down from the previous month’s 1.7 lakh shares, suggesting a shift in trading patterns as the stock approached its new highs.
Financial Trends and Profitability
Short-term financial trends show a flat overall trajectory as of June 2026. However, key positive factors include a 31.99% growth in profit after tax (PAT) for the nine-month period, reaching ₹136.89 crores, and a 20.58% increase in net sales over the latest six months, amounting to ₹340.61 crores. These figures reflect solid operational performance despite a slight 6.2% decline in quarterly PAT to ₹40.55 crores compared to the previous four-quarter average. Interest expenses have increased by 30.43% to ₹4.50 crores in the latest six months, which warrants monitoring but remains manageable given the strong interest coverage ratio.
Historical Performance Comparison
While Sudeep Pharma Ltd’s longer-term returns over three, five, and ten years are not available, its one-year performance stands out with a flat return of 0.00% compared to the Sensex’s negative 2.13%. The stock’s year-to-date gain of 61.05% is particularly notable against the Sensex’s decline, highlighting the company’s recent outperformance within the Pharmaceuticals & Biotechnology sector.
Market Capitalisation and Rating
Sudeep Pharma Ltd is classified as a small-cap company. The latest rating from MarketsMOJO assigns a Mojo Score of 58.0 with a Mojo Grade of Hold, upgraded from a previous ungraded status as of 22 May 2026. This rating reflects a balanced view of the company’s valuation and quality metrics, suggesting a stable outlook at current levels.
Summary
The attainment of an all-time high price of Rs.988.7 by Sudeep Pharma Ltd on 06 Aug 2026 marks a significant achievement for the company and its shareholders. Supported by strong recent price momentum, favourable technical indicators, and solid financial quality, the stock’s performance has outpaced broader market indices and its sector peers. While valuation multiples remain elevated, the company’s robust capital structure, healthy profitability metrics, and consistent delivery volumes underpin the sustainability of this milestone. This event underscores Sudeep Pharma’s position as a noteworthy entity within the Pharmaceuticals & Biotechnology sector.
